Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma

For decades, the selection of chemotherapeutic regimens for the treatment of recurrent or metastatic nasopharyngeal carcinoma has been mainly empirical. To our knowledge, there is no phase 3 trial that has been conducted to determine the optimal treatment for these patients before our publication. R...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Shaodong, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178081/
https://www.ncbi.nlm.nih.gov/pubmed/28007026
http://dx.doi.org/10.1186/s40880-016-0163-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5178081/
https://www.ncbi.nlm.nih.gov/pubmed/28007026
http://dx.doi.org/10.1186/s40880-016-0163-6

Ejemplares similares